RE: Nasdaq vs Aim25 Feb 2020 10:48
More from Turun Sanomat interview with Markku 22 Feb: "In December, Faron's representatives discussed further investigations with Traumakine with the US Medicines Agency (FDA). Jalkanen says that they went through the new phase III trials for Traumakini in good spirits.
Jalkanen expects the FDA to announce in the first quarter whether it will approve the research plan presented by Faron. If this happens, further investigations will begin quickly.
- We have a ready network for research, says Jalkanen."